Yes, Jenkins now with CrossBio Developement, LLC. You think maybe he might have been working with potential partners/IP acquirers over the past 3 years?...I would certainly think so. Wouldn't be shocked to see Mullan/Jenkins re-surface in some way associated with eventual go forward of anatabine...even if somewhat hidden and murky. Again, we as common shareholders left behind. Their financing deal was at minimum negligent IMO. Sure, they can hide behind the blanket excuse that most biotech startups overwhelmingly fail and they gave it their best shot...but I would shade toward "patently" inept if not downright criminal.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.